|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:zoledronic_acid
|
|
gptkbp:approvalYear
|
2007
|
|
gptkbp:ATCCode
|
gptkb:M05BA08
|
|
gptkbp:chemicalFormula
|
C5H10N2O7P2
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:drugClass
|
bisphosphonate
|
|
gptkbp:eliminationHalfLife
|
146 hours
|
|
gptkbp:form
|
solution for infusion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Reclast
|
|
gptkbp:indication
|
treatment of osteoporosis in men
treatment of osteoporosis in postmenopausal women
prevention of clinical fractures after hip fracture
treatment of glucocorticoid-induced osteoporosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:otherName
|
gptkb:Aclasta
zoledronate
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
muscle pain
renal impairment
hypocalcemia
flu-like symptoms
|
|
gptkbp:usedFor
|
gptkb:bone
gptkb:Paget's_disease_of_bone
prevention of skeletal fractures in cancer
|
|
gptkbp:bfsParent
|
gptkb:zoledronic_acid
|
|
gptkbp:bfsLayer
|
6
|